Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TB Drug Development: An Attractive Public Health Project for FDA

This article was originally published in RPM Report

Executive Summary

FDA is joining in the push for new tuberculosis treatments, with Commissioner Hamburg lending support for a renewed development effort. The challenge is to translate podium appearances into changes that will make for a more attractive development pathway. The primary goal is to find a way to study multi-drug regimens, including regimens with more than one investigational compound. FDA is engaging on that thorny regulatory issue.
Advertisement

Related Content

J&J Bedaquline and the Evolving Role for Accelerated Approval: Confirming Safety, Not Efficacy?
J&J’s Bedaquiline: 10 Days Early For GAIN Incentive
Antibiotic Early Endpoints: FDA Looking At Patient Observations
FDA Catching Antibiotic Incentive Bug: Agency Primed To Consider Ways To Shorten Route for Resistant-Strain Drugs
Data Integrity and Antibiotic Clinical Trials: FDA, Industry Try Systemic Therapy
Creating Combinations
Creating Combinations
Creating Combinations
A Critical Test for FDA's Critical Path Initiative

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel